These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1007 related articles for article (PubMed ID: 27154821)

  • 1. ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.
    Zhu L; Li Q; Wong SH; Huang M; Klein BJ; Shen J; Ikenouye L; Onishi M; Schneidawind D; Buechele C; Hansen L; Duque-Afonso J; Zhu F; Martin GM; Gozani O; Majeti R; Kutateladze TG; Cleary ML
    Cancer Discov; 2016 Jul; 6(7):770-83. PubMed ID: 27154821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation.
    Balbach ST; Orkin SH
    Cancer Discov; 2016 Jul; 6(7):700-2. PubMed ID: 27371576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Menin critically links MLL proteins with LEDGF on cancer-associated target genes.
    Yokoyama A; Cleary ML
    Cancer Cell; 2008 Jul; 14(1):36-46. PubMed ID: 18598942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammalian ASH1L is a histone methyltransferase that occupies the transcribed region of active genes.
    Gregory GD; Vakoc CR; Rozovskaia T; Zheng X; Patel S; Nakamura T; Canaani E; Blobel GA
    Mol Cell Biol; 2007 Dec; 27(24):8466-79. PubMed ID: 17923682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. hDOT1L links histone methylation to leukemogenesis.
    Okada Y; Feng Q; Lin Y; Jiang Q; Li Y; Coffield VM; Su L; Xu G; Zhang Y
    Cell; 2005 Apr; 121(2):167-78. PubMed ID: 15851025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A MENage à Trois in leukemia.
    Roudaia L; Speck NA
    Cancer Cell; 2008 Jul; 14(1):3-5. PubMed ID: 18598937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The H3K4-Methyl Epigenome Regulates Leukemia Stem Cell Oncogenic Potential.
    Wong SH; Goode DL; Iwasaki M; Wei MC; Kuo HP; Zhu L; Schneidawind D; Duque-Afonso J; Weng Z; Cleary ML
    Cancer Cell; 2015 Aug; 28(2):198-209. PubMed ID: 26190263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis.
    Yang L; Liu L; Gao H; Pinnamaneni JP; Sanagasetti D; Singh VP; Wang K; Mathison M; Zhang Q; Chen F; Mo Q; Rosengart T; Yang J
    J Hematol Oncol; 2017 Oct; 10(1):159. PubMed ID: 28974232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic strategies against hDOT1L as a potential drug target in MLL-rearranged leukemias.
    Banday S; Farooq Z; Ganai SA; Altaf M
    Clin Epigenetics; 2020 May; 12(1):73. PubMed ID: 32450905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
    Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
    Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
    Wang WT; Chen TQ; Zeng ZC; Pan Q; Huang W; Han C; Fang K; Sun LY; Yang QQ; Wang D; Luo XQ; Sun YM; Chen YQ
    J Hematol Oncol; 2020 Jun; 13(1):78. PubMed ID: 32552847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia.
    Risner LE; Kuntimaddi A; Lokken AA; Achille NJ; Birch NW; Schoenfelt K; Bushweller JH; Zeleznik-Le NJ
    J Biol Chem; 2013 Oct; 288(41):29901-10. PubMed ID: 23990460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis.
    Jin S; Zhao H; Yi Y; Nakata Y; Kalota A; Gewirtz AM
    J Clin Invest; 2010 Feb; 120(2):593-606. PubMed ID: 20093773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia.
    Kerry J; Godfrey L; Repapi E; Tapia M; Blackledge NP; Ma H; Ballabio E; O'Byrne S; Ponthan F; Heidenreich O; Roy A; Roberts I; Konopleva M; Klose RJ; Geng H; Milne TA
    Cell Rep; 2017 Jan; 18(2):482-495. PubMed ID: 28076791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Ash2L/RbBP5 heterodimer stimulates the MLL1 methyltransferase activity through coordinated substrate interactions with the MLL1 SET domain.
    Cao F; Chen Y; Cierpicki T; Liu Y; Basrur V; Lei M; Dou Y
    PLoS One; 2010 Nov; 5(11):e14102. PubMed ID: 21124902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation and structural characterization of the LEDGF/p75-MLL interface as a new target for the treatment of MLL-dependent leukemia.
    Cermáková K; Tesina P; Demeulemeester J; El Ashkar S; Méreau H; Schwaller J; Rezáčová P; Veverka V; De Rijck J
    Cancer Res; 2014 Sep; 74(18):5139-51. PubMed ID: 25082813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
    Deshpande AJ; Chen L; Fazio M; Sinha AU; Bernt KM; Banka D; Dias S; Chang J; Olhava EJ; Daigle SR; Richon VM; Pollock RM; Armstrong SA
    Blood; 2013 Mar; 121(13):2533-41. PubMed ID: 23361907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis of nucleosome recognition and modification by MLL methyltransferases.
    Xue H; Yao T; Cao M; Zhu G; Li Y; Yuan G; Chen Y; Lei M; Huang J
    Nature; 2019 Sep; 573(7774):445-449. PubMed ID: 31485071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unlike Its Paralog LEDGF/p75, HRP-2 Is Dispensable for MLL-R Leukemogenesis but Important for Leukemic Cell Survival.
    Van Belle S; El Ashkar S; Čermáková K; Matthijssens F; Goossens S; Canella A; Hodges CH; Christ F; De Rijck J; Van Vlierberghe P; Veverka V; Debyser Z
    Cells; 2021 Jan; 10(1):. PubMed ID: 33477970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.